Download Manufacturing has begun for Cancer Advances` Lead Product

FOR IMMEDIATE RELEASE
Manufacturing has begun for
Cancer Advances’ Lead Product
Durham, NC, May 5, 2016— Cancer Advances Inc., a wholly owned subsidiary of
Cato Holding Company, is excited to announce that drug manufacturing efforts for
their lead product are underway.
Manufacturing activities have been initiated for Cancer Advances’ lead product
G17DT Immunogen. This work has been contracted with Nova Laboratories
(Leicester, UK) and production of initial GMP batches are planned for this summer.
It is anticipated that production of the drug substance and subsequent manufacture
of drug product will be completed in a 3-6 month timeframe.
Cancer Advances is excited that the manufacturing activities have been initiated
and look forward to the availability of clinical trial materials for on-going studies in
the near future.
About Cancer Advances Inc.
Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a
biotechnology company focused on impacting human health and suppressing the
progression of gastrointestinal cancers by enhancing the adaptive immune
system. The company is led by an experienced management team and has a
broad intellectual property portfolio.
Please visit our product page for more information on what is in
development: http://www.canceradvancesinc.com/product.html
Contact: Lynda Sutton
President Cancer Advances, Inc.
Phone: 919-361-2162 Email: [email protected]